BioTech Co. Hit Investor Suit Over Cancer Test Trial Miss
Biotechnology company Grail Inc. was hit with a proposed investor class action alleging that it misled investors about the likelihood its cancer screening blood test would demonstrate effectiveness in a clinical...To view the full article, register now.
Already a subscriber? Click here to view full article